Legend Biotech, Merck, Otsuka—Fierce Pharma Asia
Legend Biotech, Merck, Otsuka—Fierce Pharma Asia
Legend Biotech
Legend Biotech is a global clinical-stage biopharmaceutical company pioneering the development of chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and solid tumors. Its lead product, CARVYKTI® (ciltacabtagene autoleucel), is approved for relapsed/refractory multiple myeloma and is co-developed with Johnson & Johnson.
Company Info
Sector:Cell therapy (CAR-T)
Headquarters:Somerset, New Jersey, United States
Founded:2014
Website:legendbiotech.com
Upcoming Milestones & Key Dates
Q2 2026 (reported)
Earnings
CARVYKTI Q2 sales update
H2 2026
Clinical
Earlier-line multiple myeloma data readouts
Late 2026
Clinical
Solid tumor pipeline expansion
Clinical Development Pipeline
CARVYKTI® (ciltacabtagene autoleucel)
Target: BCMA-directed CAR-TLB2102
Target: DLL3-targeted CAR-TLB1908
Target: Claudin18.2 CAR-TRecent News
Legend Biotech CEO resigns; search underway for replacement
Legend Biotech CEO resigns; search underway for replacement.
Legend CEO Ying Huang resigns; Carvykti chief named interim leader
Legend CEO Ying Huang resigns; Carvykti chief named interim leader.
Why Legend Biotech stock fell 10% despite record Carvykti sales
Why Legend Biotech stock fell 10% despite record Carvykti sales.
Leadership Team
Ying Huang
Chief Executive Officer
Steve Gavel
Chief Commercial Officer, CARVYKTI
Marc L. Harrison
Chief Medical Officer